M&A Deal Summary

Integra LifeSciences Holdings Acquires Johnson & Johnson - Codman Neurosurgery Business

On February 15, 2017, Integra LifeSciences Holdings acquired medical products company Johnson & Johnson - Codman Neurosurgery Business from Johnson & Johnson for 1.0B USD

Acquisition Highlights
  • This is Integra LifeSciences Holdings’ 35th transaction in the Medical Products sector.
  • This is Integra LifeSciences Holdings’ largest (disclosed) transaction.
  • This is Integra LifeSciences Holdings’ 35th transaction in the United States.
  • This is Integra LifeSciences Holdings’ 8th transaction in Massachusetts.

M&A Deal Summary
Date 2017-02-15
Target Johnson & Johnson - Codman Neurosurgery Business
Sector Medical Products
Buyer(s) Integra LifeSciences Holdings
Sellers(s) Johnson & Johnson
Deal Type Divestiture
Deal Value 1.0B USD

Target

Johnson & Johnson - Codman Neurosurgery Business

Raynham, Massachusetts, United States
Johnson & Johnson - Codman Neurosurgery Business is a global neurosurgery and neurovascular company that offers a broad portfolio of devices for hydrocephalus management, neuro intensive care and cranial surgery, as well as aneurysm coils, vascular reconstruction devices and other technologies used in the endovascular treatment of cerebral aneurysms and stroke.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Integra LifeSciences Holdings

Princeton, New Jersey, United States
Category Company
Founded 1989
Sector Medical Products
Employees3,946
Revenue 1.5B USD (2023)
DESCRIPTION

Integra LifeSciences Holdings is a major medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. Integra LifeSciences Holdings was founded in 1989 and is based in Princeton, New Jersey.

DEAL STATS #
Overall 42 of 45
Sector (Medical Products) 35 of 38
Type (Divestiture) 11 of 12
State (Massachusetts) 8 of 8
Country (United States) 35 of 38
Year (2017) 2 of 2
Size (of disclosed) 1 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-10 Derma Sciences

Princeton, New Jersey, United States

Derma Sciences, Inc. is an integrated manufacturer, marketer and supplier of dermatological related product lines, including: wound care, wound closure and specialty securement devices, and skin care.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-09-11 Integra LifeSciences Holdings - Neurosurgery Assets

Plainsboro, New Jersey, United States

Integra LifeSciences Holdings Corp. - Neurosurgery Assets is a provider of medical products in New Jersey.

Sell $48M

Seller(S) 1

SELLER

Johnson & Johnson

New Brunswick, New Jersey, United States
Category Company
Founded 1886
Sector Consumer Products
Employees132,000
Revenue 85.2B USD (2023)
DESCRIPTION
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.

Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.

DEAL STATS #
Overall 14 of 18
Sector (Medical Products) 6 of 7
Type (Divestiture) 13 of 16
State (Massachusetts) 1 of 1
Country (United States) 12 of 16
Year (2017) 1 of 1
Size (of disclosed) 4 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-26 Actelion

Allschwil, Switzerland

Actelion Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical need. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). The Company's portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Actelion was formed in 1997 and has its corporate headquarters in Allschwil, Switzerland.

Buy $30.0B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-04 TearScience

Morrisville, North Carolina, United States

TearScience is a medical device manufacturer dedicated to evaluating meibomian gland health and treating meibomian gland dysfunction (MGD). TearScience was founded in 2005 and is based in Morrisville, North Carolina.

Buy -
Mergr

Product

Company

Legal